A phase II B open label randomised controlled trial to evaluate the efficacy and safety of Ivermectin in reducing viral loads in patients with hematological disorders who are admitted with COVID-19 infection (ICE study)
Implementing Organization
Christian Medical College
Principal Investigator
Dr Biju George
Professor
|
Christian Medical College
About
The study aims to understand if the use of Ivermectin is associated with a more rapid clearance of the virus compared to standard supportive treatment and whether this rapid reduction will lead to better outcomes.
Patents
NA
Achievements
NA
Outcome / Output
Patients with COVID-19 infection were randomised to receive either standard of care (SOC0], single dose of 12 mg or 24 mg of Ivermectin. Serial naso-pharyngeal swabs for RT-PCR were sent on days 3, 5 and 7. All patients were followed up till hospital discharge or death. There was no difference in the RT-PCR negativity rates on days 5 and 7 or a > 2 log reduction in RTPCR between the three groups. Clinical resolution of infection and mortality were similar between the three groups.
Christian Medical College
Professor
Acces sibility Controls